Edition:
United States

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

0.92USD
19 Apr 2018
Change (% chg)

$-0.00 (-0.05%)
Prev Close
$0.92
Open
$0.92
Day's High
$0.92
Day's Low
$0.90
Volume
1,368
Avg. Vol
55,393
52-wk High
$12.40
52-wk Low
$0.75

Chart for

About

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide... (more)
No analyst recommendations are available for .

Overall

Beta: 2.58
Market Cap(Mil.): $19.23
Shares Outstanding(Mil.): 6.05
Dividend: --
Yield (%): --

Financials

  DARE.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -8.97 -- --
ROI: -126.16 1.58 14.38
ROE: -169.76 2.41 16.07

BRIEF-Dare Bioscience Says Board Increased Size To 6 Directors

* DARE BIOSCIENCE - ON APRIL 9, BOARD INCREASED SIZE OF BOARD FROM 5 DIRECTORS TO 6 DIRECTORS , ELECTED JESSICA GROSSMAN TO FILL VACANCY - SEC FILING Source: (https://bit.ly/2v7rEnA) Further company coverage:

Apr 11 2018

BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil

* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Apr 02 2018

BRIEF-Dare Bioscience Announces Development And Option Agreement With Orbis Biosciences For Long-Acting Injectable Contraceptive

* DARÉ BIOSCIENCE ANNOUNCES EXCLUSIVE DEVELOPMENT AND OPTION AGREEMENT WITH ORBIS BIOSCIENCES FOR LONG-ACTING INJECTABLE CONTRACEPTIVE

Mar 12 2018

BRIEF-Empery Asset Management Lp Reports 9.05 pct Passive Stake In Dare Bioscience As Of Feb 13

* EMPERY ASSET MANAGEMENT LP REPORTS 9.05 PERCENT PASSIVE STAKE IN DARE BIOSCIENCE INC AS OF FEB 13, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2CC1wzx) Further company coverage:

Feb 21 2018

BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil

* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER

Feb 15 2018

BRIEF-Dare Bioscience Inc To Raise About $10.25 Mln

* DARÉ BIOSCIENCE, INC. TO RAISE APPROXIMATELY $10.25 MILLION

Feb 13 2018

BRIEF-Daré Bioscience Announces Proposed Public Offering Of Common Stock

* DARÉ BIOSCIENCE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 13 2018

BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD

* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER

Feb 12 2018

BRIEF-Dare Bioscience Enters Into A License Agreement With Strategic Science And Technologies

* DARE BIOSCIENCE INC - ON FEB 11, 2018, CO ENTERED INTO A LICENSE AGREEMENT WITH STRATEGIC SCIENCE AND TECHNOLOGIES-D & STRATEGIC SCIENCE TECHNOLOGIES

Feb 12 2018

BRIEF-Dare Bioscience Says Entered Into Common Stock Sales Agreement

* DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING

Jan 04 2018

Earnings vs. Estimates